Headquartered in San Diego, CA Fiscal year ends December NASDAQ: FATE fatetherapeutics.com
Fate Therapeutics is a clinical-stage biopharmaceutical company focused on developing induced pluripotent stem cell (iPSC)-derived off-the-shelf cellular immunotherapies. The company's proprietary iPSC product platform enables the creation of multiplexed-engineered master iPSC lines used to manufacture well-defined, uniform cell therapy products that can be stored in inventory for on-demand availability. The pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates targeting autoimmune diseases and oncology. Key programs include FT819 (CD19-targeting CAR T-cell in lupus nephritis, SLE, and systemic sclerosis), FT839 (dual CD19/CD38 CAR T-cell for autoimmune diseases), and FT836 (MICA/B-targeting CAR T-cell for solid tumors including colorectal cancer). The company collaborates with Ono Pharmaceutical for preclinical development activities. Fate's intellectual property portfolio includes over 500 issued patents and 500 pending patent applications. The company trades on NASDAQ under the ticker FATE. Updated
Tuesday's top analyst upgrades and downgrades included American International Group, APA, Etsy, Goldman Sachs, Howmet Aerospace, Morgan Stanley, Wayfair, Welltower, Wendy’s and Workday .
Friday’s top analyst upgrades and downgrades included Analog Devices, Bath & Body Works, Cisco Systems, Elanco Animal Health, Exxon Mobil, Marvell Technology, MGIC Investment, Nvidia, Snowflake, Target, TJX Companies and Zoom Video…
Monday's top analyst upgrades and downgrades included Bristol-Myers Squibb, Cheniere Energy, Chewy, Costco Wholesale, CrowdStrike, Exact Sciences, Lululemon Athletica, New York Community Bancorp, Okta, Physicians Realty Trust, Spotify Technology and Welltower.
Friday’s additional top analyst upgrades and downgrades were on BankUnited, Canadian National Railway, Fate Therapeutics, Moody's, Regions Financial, Snowflake, Travelers, Voya Financial and more.
Wednesday afternoon's top analyst upgrades and downgrades included Advanced Micro Devices, Analog Devices, Applied Materials, Comcast, Chipotle Mexican Grill, Grab, IBM, Johnson & Johnson, Lyft, Oracle, Roku and Snap.
Tuesday afternoon's analyst upgrades and downgrades included Fate Therapeutics, Livent, RealReal, SmileDirectClub and more.
Thursday's top analyst upgrades and downgrades included Dick’s Sporting Goods, Fate Therapeutics, Kimberly-Clark, Nordstrom, Roblox, TJX Companies and Zoom Video Communications.
A couple of Cathie Wood's ARK Invest funds bought over 240,000 shares of Fate Therapeutics on August 3.
One of Cathie Wood's Ark Invest funds bought over 530,000 shares of Fate Therapeutics on July 7.
Monday's top analyst upgrades and downgrades included Capital One, Etsy, Fiserv, Progessive, Splunk, Ulta Beauty and Visa.
24/7 Wall St. looks at some big analyst calls that we have seen so far on Friday, including Etsy, Fate Therapeutics, Intellia, Ionis, Monster Beverage and more.
24/7 Wall St. looks at some big analyst calls that we have seen so far on Monday, including Alexion Pharma, Activision Blizzard, Baker Hughes, BioMarin, and more.
Friday's top analyst upgrades and downgrades included AIG, Best Buy, Carvana, Dell Technologies, HP, L Brands, Monster Beverage, Twitter and Zscaler.
Wedbush took a closer look at some of the companies in its coverage universe that are set to present at ASCO and what the impact may be going forward.
Wednesday's top analyst upgrades and downgrades included Bluebird Bio, Ciena, CommVault Systems, Dollar General, JD.com, Kroger, Nucor, Target and Walmart.
Fate Therapeutics is a clinical-stage biopharmaceutical company focused on developing induced pluripotent stem cell (iPSC)-derived off-the-shelf cellular immunotherapies.
The Wall Street consensus 12-month price target for FATE is $5.74.
